AH Bio Fund II, L.P. - SEC Form 4 Insider Trading Activity
Summary
Updated Aug 3, 2026
AH Bio Fund II, L.P. has filed 1 SEC Form 4 filing across 1 company in the last 90 days - buying. Lifetime open-market purchases: $5.00M.
Profile
AH Bio Fund II, L.P. is an investment firm that reports beneficial ownership of shares in Scribe Therapeutics, Inc. (SCTX) under U.S. securities law. It has submitted 1 SEC insider filing since 2026, most recently in July 2026.
| Filer type | Fund |
|---|---|
| Role | 10% Owner |
| Notability | 20/100 |
Board memberships
- Scribe Therapeutics, Inc.
Reported roles
- 10% Owner
Trading Pattern
InsiderAlpha's records for AH Bio Fund II, L.P. go back to 2026: 1 primary Form 4 filing, an average of 1.0 per year. The typical open-market purchase is $5.00M (1 buy totaling $5.00M). The largest single buy on record is $5.00M of SCTX in 2026. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Career & Filing History
Every role AH Bio Fund II, L.P. has reported on a Form 4, reconstructed from the filings themselves - reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
- 10% Owner at Scribe Therapeutics, Inc. (SCTX) - 1 filing, 2026
Recent Transactions
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-29 | SCTX | Scribe Therapeutics, Inc. | P - Open-market purchase | 333.3K | $15.00 | $5.00M |
| 2026-07-29 | SCTX | Scribe Therapeutics, Inc. | J - Other acquisition / disposition | 697.6K | - | |
| 2026-07-29 | SCTX | Scribe Therapeutics, Inc. | J - Other acquisition / disposition | 2.05M | - |
Companies - Last 90 Days
- Scribe Therapeutics, Inc. (SCTX) - 1 filing, last 2026-07-29
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades at the companies AH Bio Fund II, L.P. has recently filed at. Multiple unrelated insiders buying the same stock within a short window - cluster buying - has historically been one of the strongest Form 4 signals.
- Behzad Aghazadeh - $36.26M of SCTX open-market activity in the last 12 months
- ORBIMED ADVISORS LLC - $15.00M of SCTX open-market activity in the last 12 months
- Carl L. Gordon - $15.00M of SCTX open-market activity in the last 12 months
- Svetlana Lucas - $45K of SCTX open-market activity in the last 12 months
- David Parrot - $40K of SCTX open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
- Srinivas Akkaraju
- Amwal Investments LLC
- Apollo Principal Holdings B GP, LLC
- Apollo Principal Holdings B, L.P.
- ARCH Venture Partners XII, LLC
- ARCH Venture Partners XIII, LLC
- Audax Private Credit Business, LP
- Milton C. Ault III
Frequently Asked Questions
What is AH Bio Fund II, L.P.?
AH Bio Fund II, L.P. is an investment firm that reports beneficial ownership of shares in Scribe Therapeutics, Inc. (SCTX) under U.S. securities law. It has submitted 1 SEC insider filing since 2026, most recently in July 2026.…
How many SEC Form 4 filings has AH Bio Fund II, L.P. submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has AH Bio Fund II, L.P. been buying or selling stock?
Recorded transactions: 1 open-market purchase ($5.00M) and 0 open-market sales across all tracked filings.
Where can I see all of AH Bio Fund II, L.P.'s SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Open the live AH Bio Fund II, L.P. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.